Pathological Cardiac Hypertrophy Alters Intracellular Targeting of Phosphodiesterase Type 5 From Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling

Background In the normal heart, phosphodiesterase type 5 (PDE5) hydrolyzes cGMP coupled to nitric oxide– (specifically from nitric oxide synthase 3) but not natriuretic peptide (NP)–stimulated guanylyl cyclase. PDE5 is upregulated in hypertrophied and failing hearts and is thought to contribute to their pathophysiology. Because nitric oxide signaling declines whereas NP-derived cGMP rises in such diseases, we hypothesized that PDE5 substrate selectivity is retargeted to blunt NP-derived signaling. Methods and Results Mice with cardiac myocyte inducible PDE5 overexpression (P5+) were crossed to those lacking nitric oxide synthase 3 (N3−), and each model, the double cross, and controls were subjected to transaortic constriction. P5+ mice developed worse dysfunction and hypertrophy and enhanced NP stimulation, whereas N3− mice were protected. However, P5+/N3− mice behaved similarly to P5+ mice despite the lack of nitric oxide synthase 3–coupled cGMP generation, with protein kinase G activity suppressed in both models. PDE5 inhibition did not alter atrial natriuretic peptide–stimulated cGMP in the resting heart but augmented it in the transaortic constriction heart. This functional retargeting was associated with PDE5 translocation from sarcomeres to a dispersed distribution. P5+ hearts exhibited higher oxidative stress, whereas P5+/N3− hearts had low levels (likely owing to the absence of nitric oxide synthase 3 uncoupling). This highlights the importance of myocyte protein kinase G activity as a protection for pathological remodeling. Conclusions These data provide the first evidence for functional retargeting of PDE5 from one compartment to another, revealing a role for natriuretic peptide–derived cGMP hydrolysis by this esterase in diseased heart myocardium. Retargeting likely affects the pathophysiological consequence and the therapeutic impact of PDE5 modulation in heart disease.

[1]  M. Marletta,et al.  Structure and regulation of soluble guanylate cyclase. , 2012, Annual review of biochemistry.

[2]  R. Fischmeister,et al.  PDEs create local domains of cAMP signaling. , 2012, Journal of molecular and cellular cardiology.

[3]  B. Casadei,et al.  Sub-cellular targeting of constitutive NOS in health and disease. , 2012, Journal of molecular and cellular cardiology.

[4]  D. Kass,et al.  Pressure-Overload–Induced Subcellular Relocalization/Oxidation of Soluble Guanylyl Cyclase in the Heart Modulates Enzyme Stimulation , 2012, Circulation research.

[5]  B. French,et al.  Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium , 2012, Circulation. Heart failure.

[6]  L. R. Potter,et al.  Guanylyl cyclase structure, function and regulation. , 2011, Cellular signalling.

[7]  M. Zaccolo,et al.  cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes , 2011, Circulation research.

[8]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[9]  Dong I. Lee,et al.  Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. , 2010, Journal of the American College of Cardiology.

[10]  R. Fischmeister,et al.  Feedback Control Through cGMP-Dependent Protein Kinase Contributes to Differential Regulation and Compartmentation of cGMP in Rat Cardiac Myocytes , 2010, Circulation research.

[11]  J. Corbin,et al.  cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action , 2010, Pharmacological Reviews.

[12]  K. Nakao,et al.  Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart , 2010, Circulation research.

[13]  Xinli Hu,et al.  Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing Heart , 2010, Circulation.

[14]  Martin J. Lohse,et al.  β2-Adrenergic Receptor Redistribution in Heart Failure Changes cAMP Compartmentation , 2010, Science.

[15]  M. Houslay Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.

[16]  Dong I. Lee,et al.  PDE5A suppression of acute β-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation , 2010, Basic Research in Cardiology.

[17]  H. Otani The role of nitric oxide in myocardial repair and remodeling. , 2009, Antioxidants & redox signaling.

[18]  K. Sipido,et al.  Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice , 2009, Circulation.

[19]  D. Kass,et al.  Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. , 2009, Journal of the American College of Cardiology.

[20]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. , 2009, The Journal of clinical investigation.

[21]  Hisham S. Elbatarny,et al.  Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions , 2008, Proceedings of the National Academy of Sciences.

[22]  D. Kass,et al.  Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil , 2008, Journal of Pharmacology and Experimental Therapeutics.

[23]  R. Arena,et al.  Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.

[24]  P. Light,et al.  Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.

[25]  Xin Xu,et al.  Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations. , 2007, American journal of physiology. Renal physiology.

[26]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[27]  D. Kass,et al.  Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. , 2007, Journal of the American College of Cardiology.

[28]  Jordan T. Shin,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[29]  M. Lohse,et al.  Cyclic AMP Imaging in Adult Cardiac Myocytes Reveals Far-Reaching &bgr;1-Adrenergic but Locally Confined &bgr;2-Adrenergic Receptor–Mediated Signaling , 2006, Circulation research.

[30]  L. Langeberg,et al.  AKAP signaling complexes: getting to the heart of the matter. , 2006, Trends in molecular medicine.

[31]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[32]  M. Picard,et al.  Nitric oxide synthase 2 and pressure‐overload‐induced left ventricular remodelling in mice , 2006, Experimental physiology.

[33]  U. Förstermann,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.

[34]  S. Reiken,et al.  Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias , 2005, Cell.

[35]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[36]  Anindita Das,et al.  Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis , 2005, Journal of Biological Chemistry.

[37]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[38]  M. Guazzi,et al.  The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. , 2004, Journal of the American College of Cardiology.

[39]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[40]  R. Karas,et al.  Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.

[41]  G. Baillie,et al.  Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. , 2003, Cellular signalling.

[42]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[43]  R. Lefkowitz,et al.  Retraction for Baillie et al., β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  P. Huang,et al.  Modulation of mouse cardiac function in vivo by eNOS and ANP. , 2000, American journal of physiology. Heart and circulatory physiology.

[46]  K. Margulies,et al.  Inhibition of cyclic GMP phosphodiesterases augments renal responses to atrial natriuretic factor in congestive heart failure. , 1994, Journal of cardiac failure.

[47]  M. Wilkins,et al.  Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. , 1993, The Journal of clinical investigation.

[48]  F. Laurindo,et al.  Assessment of superoxide production and NADPH oxidase activity by HPLC analysis of dihydroethidium oxidation products. , 2008, Methods in enzymology.

[49]  R. Lefkowitz,et al.  beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. , 2003, Proceedings of the National Academy of Sciences of the United States of America.